Home > Research > Publications & Outputs > Targeting the Cell Cycle in the Pursuit of Nove...

Electronic data

  • CurrPharmDesign2008_corrected.pdf

    670 KB, PDF document

Links

View graph of relations

Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa. / Grant, Karen M.
In: Current Pharmaceutical Design, Vol. 14, No. 9, 2008, p. 917-924.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Author

Grant, Karen M. / Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 9. pp. 917-924.

Bibtex

@article{2fe268848c2c4ce9abedb1ed3d73697b,
title = "Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa.",
abstract = "Protozoan parasites, such as those responsible for malaria and African Sleeping Sickness, represent a huge burden to the developing world. Current chemotherapy to combat these diseases is inadequate: antiquated, toxic and increasingly ineffective due to drug resistance. In this article, the potential usefulness of targeting key regulators of the parasite cell cycle will be discussed, paying particular attention to three families of protein kinases: Cyclin-dependent kinases, glycogen synthase kinases and Aurora kinases. This review shall outline their identification, which has been greatly accelerated by the availability of parasite genome data, their validation as bona fide regulators of the parasite cell cycle and current data on the availability and anti-parasite activity of inhibitors.",
keywords = "Cyclin-dependent kinase Glycogen synthase kinase Aurora kinase cell cycle Trypanosoma Leishmania Plasmodium",
author = "Grant, {Karen M.}",
year = "2008",
language = "English",
volume = "14",
pages = "917--924",
journal = "Current Pharmaceutical Design",
issn = "1873-4286",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

RIS

TY - JOUR

T1 - Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies against Parasitic Protozoa.

AU - Grant, Karen M.

PY - 2008

Y1 - 2008

N2 - Protozoan parasites, such as those responsible for malaria and African Sleeping Sickness, represent a huge burden to the developing world. Current chemotherapy to combat these diseases is inadequate: antiquated, toxic and increasingly ineffective due to drug resistance. In this article, the potential usefulness of targeting key regulators of the parasite cell cycle will be discussed, paying particular attention to three families of protein kinases: Cyclin-dependent kinases, glycogen synthase kinases and Aurora kinases. This review shall outline their identification, which has been greatly accelerated by the availability of parasite genome data, their validation as bona fide regulators of the parasite cell cycle and current data on the availability and anti-parasite activity of inhibitors.

AB - Protozoan parasites, such as those responsible for malaria and African Sleeping Sickness, represent a huge burden to the developing world. Current chemotherapy to combat these diseases is inadequate: antiquated, toxic and increasingly ineffective due to drug resistance. In this article, the potential usefulness of targeting key regulators of the parasite cell cycle will be discussed, paying particular attention to three families of protein kinases: Cyclin-dependent kinases, glycogen synthase kinases and Aurora kinases. This review shall outline their identification, which has been greatly accelerated by the availability of parasite genome data, their validation as bona fide regulators of the parasite cell cycle and current data on the availability and anti-parasite activity of inhibitors.

KW - Cyclin-dependent kinase Glycogen synthase kinase Aurora kinase cell cycle Trypanosoma Leishmania Plasmodium

M3 - Journal article

VL - 14

SP - 917

EP - 924

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1873-4286

IS - 9

ER -